Galena Biopharma (GALE) Announces Presentation of GALE-301 Phase 1/2a Data in Certain Cancers at ASCO
Tweet Send to a Friend
Galena Biopharma, Inc. (Nasdaq: GALE) announced the primary analysis from the Company’s GALE-301 Phase 1/2a clinical trial at the American ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
